[Federal Register Volume 65, Number 27 (Wednesday, February 9, 2000)]
[Notices]
[Page 6395]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-2874]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Registration

    By Notice dated October 8, 1999, and published in the Federal 
Register on October 18, 1999, (64 FR 56226), Glaxo Wellcome, Inc., 
Attn: Jeffrey A. Weiss, 1011 North Arendell Avenue, PO Box 1217, 
Zebulon, North Carolina 27597-2309, made application to the Drug 
Enforcement Administration to be registered as an importer of 
Remifentanil (9739), a basic class of controlled substance listed in 
Schedule II.
    The remifentanil is being imported for the production of Ultiva 
dosage forms and for research and new product development.
    No comments or objections have been received. DEA has considered 
the factors in Title 21, United States Code, Section 823(a) and 952(a), 
and determined that the registration of Glaxo Wellcome, Inc. to import 
remifantanil is consistent with the public interest and with United 
States obligations under international treaties, conventions, or 
protocols in effect on May 1, 1971, at this time. DEA has investigated 
the firm on a regular basis to ensure that the company's continued 
registration is consistent with the public interest. These 
investigations have included inspection and testing of the company's 
physical security systems, audits of the company's records, 
verification of the company's compliance with state and local laws, and 
a review of the company's background and history. Therefore, pursuant 
to section 1008(a) of the Controlled Substances Import and Export Act 
and in accordance with Title 21, Code of Federal Regulations, 
Sec. 1301.34, the above firm is granted registration as an importer of 
the basic class of controlled substance listed above.

    Dated: January 4, 2000.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 00-2874 Filed 2-8-00; 8:45 am]
BILLING CODE 4410-09-M